167 related articles for article (PubMed ID: 35200148)
21. Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian.
Hessock M; Brewer T; Hutson S; Anderson J
Nurs Womens Health; 2021 Jun; 25(3):187-197. PubMed ID: 33933425
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
23. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.
Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M
Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661
[TBL] [Abstract][Full Text] [Related]
24. Population-based genetic testing for Women's cancer prevention.
Evans O; Gaba F; Manchanda R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():139-153. PubMed ID: 32245629
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the performance of National Comprehensive Cancer Network (NCCN) breast and ovarian genetic/familial high risk assessment referral criteria for breast cancer women in an Asian surgical breast clinic.
Lim GH; Borje E; Allen JC
Gland Surg; 2017 Feb; 6(1):35-42. PubMed ID: 28210550
[TBL] [Abstract][Full Text] [Related]
26. Protocol to evaluate sequential electronic health record-based strategies to increase genetic testing for breast and ovarian cancer risk across diverse patient populations in gynecology practices.
Symecko H; Schnoll R; Beidas RS; Bekelman JE; Blumenthal D; Bauer AM; Gabriel P; Boisseau L; Doucette A; Powers J; Cappadocia J; McKenna DB; Richardville R; Cuff L; Offer R; Clement EG; Buttenheim AM; Asch DA; Rendle KA; Shelton RC; Fayanju OM; Wileyto EP; Plag M; Ware S; Shulman LN; Nathanson KL; Domchek SM
Implement Sci; 2023 Nov; 18(1):57. PubMed ID: 37932730
[TBL] [Abstract][Full Text] [Related]
27. Psychometric testing of the decisional conflict scale: genetic testing hereditary breast and ovarian cancer.
Katapodi MC; Munro ML; Pierce PF; Williams RA
Nurs Res; 2011; 60(6):368-77. PubMed ID: 22048556
[TBL] [Abstract][Full Text] [Related]
28. Cancer surveillance behaviors in women presenting for clinical BRCA genetic susceptibility testing.
Loescher LJ; Lim KH; Leitner O; Ray J; D'Souza J; Armstrong CM
Oncol Nurs Forum; 2009 Mar; 36(2):E57-67. PubMed ID: 19273395
[TBL] [Abstract][Full Text] [Related]
29. Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.
Marmolejo DH; Wong MYZ; Bajalica-Lagercrantz S; Tischkowitz M; Balmaña J;
Eur J Med Genet; 2021 Dec; 64(12):104350. PubMed ID: 34606975
[TBL] [Abstract][Full Text] [Related]
30. National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.
Childers CP; Childers KK; Maggard-Gibbons M; Macinko J
J Clin Oncol; 2017 Dec; 35(34):3800-3806. PubMed ID: 28820644
[TBL] [Abstract][Full Text] [Related]
31. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
33. A new paradigm of genetic testing for hereditary breast/ovarian cancers.
Kwong A; Chen JW; Shin VY
Hong Kong Med J; 2016 Apr; 22(2):171-7. PubMed ID: 26980575
[TBL] [Abstract][Full Text] [Related]
34. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
Beitsch PD; Whitworth PW; Hughes K; Patel R; Rosen B; Compagnoni G; Baron P; Simmons R; Smith LA; Grady I; Kinney M; Coomer C; Barbosa K; Holmes DR; Brown E; Gold L; Clark P; Riley L; Lyons S; Ruiz A; Kahn S; MacDonald H; Curcio L; Hardwick MK; Yang S; Esplin ED; Nussbaum RL
J Clin Oncol; 2019 Feb; 37(6):453-460. PubMed ID: 30526229
[TBL] [Abstract][Full Text] [Related]
35. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels.
Lee K; Seifert BA; Shimelis H; Ghosh R; Crowley SB; Carter NJ; Doonanco K; Foreman AK; Ritter DI; Jimenez S; Trapp M; Offit K; Plon SE; Couch FJ
Genet Med; 2019 Jul; 21(7):1497-1506. PubMed ID: 30504931
[TBL] [Abstract][Full Text] [Related]
36. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer and ovarian cancer genetics.
Edlich RF; Winters KL; Lin KY
J Long Term Eff Med Implants; 2005; 15(5):533-45. PubMed ID: 16218901
[TBL] [Abstract][Full Text] [Related]
38. Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer.
Sutcliffe S; Pharoah PD; Easton DF; Ponder BA
Int J Cancer; 2000 Jul; 87(1):110-7. PubMed ID: 10861460
[TBL] [Abstract][Full Text] [Related]
39. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
Daly MB; Pilarski R; Yurgelun MB; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Garber JE; Goggins M; Hutton ML; Khan S; Klein C; Kohlmann W; Kurian AW; Laronga C; Litton JK; Mak JS; Menendez CS; Merajver SD; Norquist BS; Offit K; Pal T; Pederson HJ; Reiser G; Shannon KM; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Dwyer MA; Darlow SD
J Natl Compr Canc Netw; 2020 Apr; 18(4):380-391. PubMed ID: 32259785
[TBL] [Abstract][Full Text] [Related]
40. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
